Abstract:Background Stimulator of interferon genes (STING) is an innate immune sensor of cytoplasmic double-stranded DNA originating from microorganisms and host cells. The activation of cytosolic DNA-STING pathway in tumor microenvironments is usually linked to more robust adaptive immune responses to tumors, however the intracellular function of STING in regulatory T cells is largely unknown. In the present study, we aimed to explore the contribution of intracellular STING activation to regulatory T cell induction (iTreg) in cervical cancer (CC) microenvironments. Methods Blood samples and tumor specimens were obtained from patients with CC. The intratumoral STING, CCL22, CD8 and forkhead box P3 (FOXP3) expression levels were measured by immunohistochemistry. T cell-specific STING conditional knockout mice (CD4-Cre/STING(flox/flox), TKO) were generated, and syngeneic TC-1 tumor model were investigated. The differentiation and molecular regulatory pathway of human and murine iTreg under different treatments were investigated by ex vivo assays, immunoblotting and quantitative PCR. Tumor-associated exosomes (T-EXO) were isolated from CC cell lines and exosomal contents were identified by ELISA and Western blot analysis. The impact of T-EXO on T cell differentiation was tested in in vitro cell culture. Results Increased STING, CCL22 level, FOXP3(+) cells but decreased CD8(+) cells in tumor tissues predicted poor survival. Tumor-bearing CD4-Cre-STING(flox/flox) (TKO) mice displayed slower tumor growth tendencies as well as fewer FOXP3(+) cells but higher CD8(+) cell proportion in tumor tissues than wild-type (WT) mice. Activating of STING signaling cooperated with T cell receptor, interleukin-2 receptor and transforming growth factor-beta (TGF-beta) signals to promote CD4(+)CD25(high)FOXP3(+) iTreg differentiation from both human and murine CD4(+)-naive T cells from WT and IFNAR(-/-) mice but not TKO or IRF3(-/-) mice in vitro. Ectopic STING, TBK1 or IRF3 expression promoted iTreg differentiation from human CD4(+)-naive T cells. T cell-intrinsic STING activation induced FOXP3 transcription through TBK1-IRF3-mediated SMAD3 and STAT5 phosphorylation independent of interferon-beta. In CC, tumor-derived exosomes activated STING signaling in tumor-infiltrated T cells by exosomal TGF-beta, cyclic GMP-AMP synthase and 2'-3'-cGAMP, leading to iTreg expansion. Conclusions These findings highlight a novel mechanism for iTreg expansion mediated by tumor-derived exosome-activated T cell-intrinsic STING signal, and provide a rationale for developing immunotherapeutic strategies targeting STING signal in CC.

ER-localized JmjC domain-containing protein JMJD8 targets STING to promote immune evasion and tumor growth in breast cancer

Γδ T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-β Signaling Pathways.

STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death

Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer

Pleiotropic anti-cancer effects of STING in estrogen receptor positive breast cancer cells.

Targeting the STING Pathway in Tumor-Associated Macrophages Regulates Innate Immune Sensing of Gastric Cancer Cells.

Tumor-derived Jagged1 promotes cancer progression through immune evasion

STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

JmjC domain-containing protein 8 (JMJD8) represses Ku70/Ku80 expression via attenuating AKT/NF-κB/COX-2 signaling.

Data from Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell–Mediated Tumor Killing

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2

Targeting JMJD1C to selectively disrupt tumor T reg cell fitness enhances antitumor immunity

STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity

495P Intrinsic STING of CD8+T Cells Regulates Self-Metabolic Reprogramming and Exerts Anti-Tumor Effects

KDM5 Histone Demethylases Repress Immune Response Via Suppression of STING

Targeting JMJD1C to Selectively Disrupt Tumor Treg Cell Fitness Enhances Antitumor Immunity

ZMYND8 expression in breast cancer cells blocks T-lymphocyte surveillance to promote tumor growth